2018
Glucose metabolism dysregulation at the onset of mental illness is not limited to first episode psychosis: A systematic review and meta‐analysis
Kucukgoncu S, Kosir U, Zhou E, Sullivan E, Srihari VH, Tek C. Glucose metabolism dysregulation at the onset of mental illness is not limited to first episode psychosis: A systematic review and meta‐analysis. Early Intervention In Psychiatry 2018, 13: 1021-1031. PMID: 30277314, PMCID: PMC6445792, DOI: 10.1111/eip.12749.Peer-Reviewed Original ResearchConceptsFirst-episode psychosisSevere mental illnessGlucose metabolism outcomesTreatment-naïveEpisode psychosisMood disordersMental illnessSystematic reviewGlucose tolerance test resultsInsulin resistance levelsImpaired glucose metabolismFirst-episode patientsTolerance test resultsHigh-risk groupMood disorder groupGlucose intoleranceEpisode patientsDiabetes developmentMetabolism dysregulationEligible studiesHealthy controlsHigh insulinFEP groupGlucose metabolismPatients
2014
High Rates of Obstructive Sleep Apnea Symptoms Among Patients With Schizophrenia
Annamalai A, Palmese LB, Chwastiak LA, Srihari VH, Tek C. High Rates of Obstructive Sleep Apnea Symptoms Among Patients With Schizophrenia. Journal Of The Academy Of Consultation-Liaison Psychiatry 2014, 56: 59-66. PMID: 25023923, PMCID: PMC5583522, DOI: 10.1016/j.psym.2014.02.009.Peer-Reviewed Original ResearchConceptsObstructive sleep apneaSevere mental illnessSTOP questionnaireSleep apneaHigh riskLarge urban community mental health centerMental illnessDiagnosis of OSAUrban community mental health centerCommunity mental health centerBody mass indexHigh-risk groupCross-sectional studyHigh clinical utilityMental health centersSample of outpatientsHigh rateOSA symptomsCardiovascular morbiditySurgical populationMass indexRisk factorsHealth centersSTOP scoreClinical utility
2013
Investigating the safety and efficacy of naltrexone for anti-psychotic induced weight gain in severe mental illness: study protocol of a double-blind, randomized, placebo-controlled trial
Tek C, Guloksuz S, Srihari VH, Reutenauer EL. Investigating the safety and efficacy of naltrexone for anti-psychotic induced weight gain in severe mental illness: study protocol of a double-blind, randomized, placebo-controlled trial. BMC Psychiatry 2013, 13: 176. PMID: 23805859, PMCID: PMC3702521, DOI: 10.1186/1471-244x-13-176.Peer-Reviewed Original ResearchConceptsSevere mental illnessEfficacy of naltrexoneWeight gainOutcome measurementsHealth problemsMental illnessGreater New Haven areaTumor necrosis factor alphaWeight lossCurrent available medicationsPlacebo-controlled trialHigh-sensitivity CRPOpioid receptor antagonistSecondary outcome measuresSerum lipid profilePrimary outcome measurementBody mass indexD2 receptor blockadeEffects of naltrexoneNovel pharmacological optionsNecrosis factor alphaDoses of naltrexoneMajor health problemRates of obesitySignificant weight loss
2012
Obese Schizophrenia Spectrum Patients Have Significantly Higher 10-Year General Cardiovascular Risk and Vascular Ages than Obese Individuals without Severe Mental Illness
Ratliff JC, Palmese LB, Reutenauer EL, Srihari VH, Tek C. Obese Schizophrenia Spectrum Patients Have Significantly Higher 10-Year General Cardiovascular Risk and Vascular Ages than Obese Individuals without Severe Mental Illness. Journal Of The Academy Of Consultation-Liaison Psychiatry 2012, 54: 67-73. PMID: 22664309, PMCID: PMC3435456, DOI: 10.1016/j.psym.2012.03.001.Peer-Reviewed Original ResearchConceptsSevere mental illnessGeneral CVD riskSchizophrenia spectrum patientsVascular ageCVD riskSpectrum patientsNHANES participantsMetabolic riskMental illnessGeneral cardiovascular riskMean vascular ageSystolic blood pressureCardiovascular disease mortalityPrimary care cliniciansHDL cholesterol levelsNutrition Examination SurveyCVD eventsCardiovascular riskObese controlsObese patientsBlood pressureCare cliniciansHypertension treatmentSmoking statusExamination Survey